Our Algo Engine triggered a buy signal recently in Healthscope and we continue to see upside potential.
HSO has announced the sale of its Asian Pathology business to TPG Capital Asia for A$279 million. The transaction is expected to be completed by the end of August 2018.
You're not a member! Trial today
Cash proceeds from the sale will be used to pay down debt and fund new domestic development plans.
The potential for M&A activity, along with the retracement in share price, makes HSO an attractive consideration supported by 3% dividend yield.
Healthscope
